Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund Sentiment Is Stagnant On Bellicum Pharmaceuticals Inc (BLCM)

Page 1 of 2

A market correction in the third quarter, spurred by a number of global macroeconomic concerns ended up having a negative impact on the markets and many hedge funds as a result. The stocks of smaller companies were especially hard hit during this time as investors fled to investments seen as being safer. This is evident in the fact that the Russell 2000 ETF underperformed the S&P 500 ETF by 14 percentage points between June 25 and the end of October. We also received indications that hedge funds were trimming their positions amid the market volatility and uncertainty, and given their greater inclination towards smaller cap stocks than other investors, it follows that a stronger sell-off occurred in those stocks. Let’s study the hedge fund sentiment to see how those concerns affected their ownership of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) during the quarter.

Hedge fund interest in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) shares was flat at the end of last quarter. This is usually a negative indicator. At the end of this article we will also compare BLCM to other stocks, including Ruby Tuesday, Inc. (NYSE:RT), Peabody Energy Corporation (NYSE:BTU), and Oriental Financial Group Inc. (NYSE:OFG) to get a better sense of its popularity.

Follow Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)
Trade (NASDAQ:BLCM) Now!

According to most market participants, hedge funds are viewed as unimportant, old investment vehicles of years past. While there are more than 8000 funds in operation at present, Our experts hone in on the bigwigs of this group, around 700 funds. Most estimates calculate that this group of people handle most of the hedge fund industry’s total capital, and by following their matchless stock picks, Insider Monkey has formulated various investment strategies that have historically outpaced the market. Insider Monkey’s small-cap hedge fund strategy outrun the S&P 500 index by 12 percentage points per annum for a decade in their back tests.

Keeping this in mind, we’re going to check out the fresh action regarding Bellicum Pharmaceuticals Inc (NASDAQ:BLCM).

What does the smart money think about Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)?

At Q3’s end, a total of 15 of the hedge funds tracked by Insider Monkey held long positions in this stock, unchanged from one quarter earlier. With the smart money’s sentiment swirling, there exists a few key hedge fund managers who were increasing their holdings significantly (or already accumulated large positions).

According to Insider Monkey’s hedge fund database, Baker Bros. Advisors, managed by Julian Baker and Felix Baker, holds the number one position in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM). The fund has a $60.9 million position in the stock, comprising 0.6% of its 13F portfolio. Coming in second is Israel Englander of Millennium Management, with a $14.4 million position; the fund has less than 0.1%% of its 13F portfolio invested in the stock. Other peers that hold long positions encompass Ken Griffin’s Citadel Investment Group, Joseph Edelman’s Perceptive Advisors and Daniel Gold’s QVT Financial.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!